PT  - JOURNAL ARTICLE
AU  - Thomas, Tiffany
AU  - Stefanoni, Davide
AU  - Reisz, Julie A.
AU  - Nemkov, Travis
AU  - Bertolone, Lorenzo
AU  - Francis, Richard O
AU  - Hudson, Krystalyn E.
AU  - Zimring, James C.
AU  - Hansen, Kirk C.
AU  - Hod, Eldad A.
AU  - Spitalnik, Steven L.
AU  - D’Alessandro, Angelo
TI  - COVID-19 infection results in alterations of the kynurenine pathway and fatty acid metabolism that correlate with IL-6 levels and renal status
AID  - 10.1101/2020.05.14.20102491
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.14.20102491
4099  - http://medrxiv.org/content/early/2020/05/16/2020.05.14.20102491.short
4100  - http://medrxiv.org/content/early/2020/05/16/2020.05.14.20102491.full
AB  - Previous studies suggest a role for systemic reprogramming of host metabolism during viral pathogenesis to fuel rapidly expanding viral proliferation, for example by providing free amino acids and fatty acids as building blocks. In addition, general alterations in metabolism can provide key understanding of pathogenesis. However, little is known about the specific metabolic effects of SARS-COV-2 infection. The present study evaluated the serum metabolism of COVID-19 patients (n=33), identified by a positive nucleic acid test of a nasopharyngeal swab, as compared to COVID-19-negative control patients (n=16). Targeted and untargeted metabolomics analyses specifically identified alterations in the metabolism of tryptophan into the kynurenine pathway, which is well-known to be involved in regulating inflammation and immunity. Indeed, the observed changes in tryptophan metabolism correlated with serum interleukin-6 (IL-6) levels. Metabolomics analysis also confirmed widespread dysregulation of nitrogen metabolism in infected patients, with decreased circulating levels of most amino acids, except for tryptophan metabolites in the kynurenine pathway, and increased markers of oxidant stress (e.g., methionine sulfoxide, cystine), proteolysis, and kidney dysfunction (e.g., creatine, creatinine, polyamines). Increased circulating levels of glucose and free fatty acids were also observed, consistent with altered carbon homeostasis in COVID-19 patients. Metabolite levels in these pathways correlated with clinical laboratory markers of inflammation and disease severity (i.e., IL-6 and C-reactive protein) and renal function (i.e., blood urea nitrogen). In conclusion, this initial observational study of the metabolic consequences of COVID-19 infection in a clinical cohort identified amino acid metabolism (especially kynurenine and cysteine/taurine) and fatty acid metabolism as correlates of COVID-19, providing mechanistic insights, potential markers of clinical severity, and potential therapeutic targets.Key pointsMetabolism of tryptophan into the kynurenine pathway is increased in COVID-19 patientsCOVID-19 infection is significantly associated with dysregulated nitrogen and carbon metabolismCOVID-19 infection induces increased circulating levels of free fatty acids and glucoseCompeting Interest StatementThough unrelated to the contents of this manuscript, the authors declare that AD, KCH, and TN are founders of Omix Technologies Inc and Altis Biosciences LLC. AD and SLS are consultants for Hemanext Inc. SLS is also a consultant for Tioma, Inc. JCZ is a consultant for Rubius Therapeutics. All the other authors disclose no conflicts of interest relevant to this study.Funding StatementThis research was supported by funds from the Boettcher Webb-Waring Investigator Award (ADA), RM1GM131968 (ADA and KCH) from the National Institute of General and Medical Sciences, and R01HL146442 (ADA), R01HL149714 (ADA), R01HL148151 (ADA, SLS), R21HL150032 (ADA), and T32 HL007171 (TN) from the National Heart, Lung, and Blood Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data and statistical elaborations are provided as supplementary files